Clinical Trial Update: Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update shows the early-phase study of ABC294640 (opaganib) in refractory/relapsed diffuse large B-cell lymphoma and Kaposi sarcoma has been withd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Kaposi Sarcoma

Drugs mentioned

• ABC294640 (Opaganib) (opaganib)

Snippet

Sponsor: RedHill Biopharma Limited | Conditions: Diffuse Large B Cell Lymphoma, Kaposi Sarcoma | Phase 1, Phase 2 | Status: WITHDRAWN